TLPH
Talphera Inc
NASDAQ · Pharmaceuticals
$0.81
+0.03 (+3.21%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 15.18M | 15.27M | 16.61M |
| Net Income | 3.38M | 4.70M | 4.66M |
| EPS | — | — | — |
| Profit Margin | 22.3% | 30.8% | 28.0% |
| Rev Growth | +21.2% | -3.4% | +2.7% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 11.00M | 9.67M | 9.42M |
| Total Equity | 26.75M | 27.14M | 24.11M |
| D/E Ratio | 0.41 | 0.36 | 0.39 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 5.75M | 6.30M | 6.21M |
| Free Cash Flow | 2.69M | 4.04M | 4.00M |